U S PHYSICAL THERAPY INC /NV (USPH) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 1.21%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 1.21% | Share-based compensation / revenue. Period ending 2026-06-30. $9.86M ÷ $812.20M × 100 ≈ 1.21% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | 812.20M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 9.86M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 76.52M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $812.20M | $9.86M | $76.52M | (m) | (m) | 1.21% | (m) | (m) |
| 2026-03-31 | (m) | $795.49M | $8.81M | $79.52M | (m) | (m) | 1.11% | (m) | (m) |
| 2025-12-31 | (m) | $780.99M | $8.27M | $86.68M | (m) | (m) | 1.06% | (m) | (m) |
| 2025-09-30 | (m) | $758.71M | $8.14M | $89.78M | (m) | (m) | 1.07% | (m) | (m) |
| 2025-06-30 | (m) | $729.61M | $7.79M | $77.30M | (m) | (m) | 1.07% | (m) | (m) |
| 2025-03-31 | (m) | $699.46M | $7.60M | $67.93M | (m) | (m) | 1.09% | (m) | (m) |
| 2024-12-31 | (m) | $671.35M | $7.82M | $63.21M | (m) | (m) | 1.17% | (m) | (m) |
| 2024-09-30 | (m) | $645.70M | $7.62M | $47.80M | (m) | (m) | 1.18% | (m) | (m) |
| 2024-06-30 | (m) | $627.67M | $7.56M | $48.93M | (m) | (m) | 1.20% | (m) | (m) |
| 2024-03-31 | (m) | $611.97M | $7.43M | $49.38M | (m) | (m) | 1.21% | (m) | (m) |
| 2023-12-31 | (m) | $604.80M | $7.24M | $52.06M | (m) | (m) | 1.20% | (m) | (m) |
| 2023-09-30 | (m) | $591.18M | $7.25M | $59.73M | (m) | (m) | 1.23% | (m) | (m) |
| 2023-06-30 | (m) | $580.78M | $7.20M | $58.75M | (m) | (m) | 1.24% | (m) | (m) |
| 2023-03-31 | (m) | $569.95M | $7.22M | $58.77M | (m) | (m) | 1.27% | (m) | (m) |
| 2022-12-31 | (m) | $553.14M | $7.26M | $56.80M | (m) | (m) | 1.31% | (m) | (m) |
| 2022-09-30 | (m) | $541.79M | $7.05M | $66.47M | (m) | (m) | 1.30% | (m) | (m) |
| 2022-06-30 | (m) | $528.09M | $8.12M | $68.51M | (m) | (m) | 1.54% | (m) | (m) |
| 2022-03-31 | (m) | $514.36M | $8.06M | $70.66M | (m) | (m) | 1.57% | (m) | (m) |
| 2021-12-31 | (m) | $495.02M | $7.87M | $70.65M | (m) | (m) | 1.59% | (m) | (m) |
| 2021-09-30 | (m) | $482.65M | $8.87M | $72.39M | (m) | (m) | 1.84% | (m) | (m) |
| 2021-06-30 | (m) | $465.69M | $7.93M | $75.39M | (m) | (m) | 1.70% | (m) | (m) |
| 2021-03-31 | (m) | $422.62M | $7.68M | $63.42M | (m) | (m) | 1.82% | (m) | (m) |
| 2020-12-31 | (m) | $422.97M | $7.92M | $52.41M | (m) | (m) | 1.87% | (m) | (m) |
| 2020-09-30 | (m) | $427.62M | $7.05M | $49.50M | (m) | (m) | 1.65% | (m) | (m) |
| 2020-06-30 | (m) | $435.94M | $6.82M | $46.38M | (m) | (m) | 1.56% | (m) | (m) |
| 2020-03-31 | (m) | $478.45M | $7.14M | $56.01M | (m) | (m) | 1.49% | (m) | (m) |
| 2019-12-31 | (m) | $481.97M | $6.99M | $67.42M | $2.08M | (m) | 1.45% | 32.43× | Reported |
| 2019-09-30 | (m) | $477.20M | $6.75M | $66.94M | $1.89M | (m) | 1.41% | 35.48× | Reported |
| 2019-06-30 | (m) | $473.07M | $6.56M | $65.56M | $1.91M | (m) | 1.39% | 34.34× | Reported |
| 2019-03-31 | (m) | $461.80M | $6.29M | $62.69M | (m) | (m) | 1.36% | (m) | (m) |
| 2018-12-31 | (m) | $453.91M | $5.94M | $60.31M | $2.04M | (m) | 1.31% | 29.54× | Reported |
| 2018-09-30 | (m) | $445.76M | $6.08M | $59.47M | $8.96M | (m) | 1.36% | 6.64× | Reported |
| 2018-06-30 | (m) | $435.68M | $5.62M | $56.93M | $11.55M | (m) | 1.29% | 4.93× | Reported |
| 2018-03-31 | (m) | $424.83M | $5.13M | $55.58M | $17.23M | (m) | 1.21% | 3.22× | Reported |
| 2017-12-31 | (m) | $414.05M | $5.03M | $54.73M | $21.06M | (m) | 1.22% | 2.60× | Reported |
| 2017-09-30 | (m) | $395.71M | $4.62M | $51.72M | $15.10M | (m) | 1.17% | 3.43× | Reported |
| 2017-06-30 | (m) | $381.02M | $4.82M | $50.89M | $15.12M | (m) | 1.27% | 3.37× | Reported |
| 2017-03-31 | (m) | $367.20M | $5.02M | $50.24M | $12.47M | (m) | 1.37% | 4.03× | Reported |
| 2016-12-31 | (m) | $356.55M | $4.96M | $49.53M | $11.48M | (m) | 1.39% | 4.32× | Reported |
| 2016-09-30 | (m) | $352.41M | $4.87M | $51.19M | $1.22M | (m) | 1.38% | 41.96× | Reported |
| 2016-06-30 | (m) | $348.11M | $4.77M | $51.08M | $1.15M | (m) | 1.37% | 44.46× | Reported |
| 2016-03-31 | (m) | $340.97M | $4.72M | $49.60M | $1.07M | (m) | 1.38% | 46.18× | Reported |
| 2015-12-31 | (m) | $331.30M | $4.49M | $47.29M | $1.03M | (m) | 1.36% | 45.87× | Reported |
| 2015-09-30 | (m) | $323.97M | $4.28M | $45.44M | $1.03M | (m) | 1.32% | 44.07× | Reported |
| 2015-06-30 | (m) | $317.63M | $3.98M | $44.77M | $1.01M | (m) | 1.25% | 44.19× | Reported |
| 2015-03-31 | (m) | $312.55M | $3.62M | $45.44M | $1.10M | (m) | 1.16% | 41.31× | Reported |
| 2014-12-31 | (m) | $305.07M | $3.36M | $45.77M | $1.09M | (m) | 1.10% | 42.07× | Reported |
| 2014-09-30 | (m) | $294.29M | $3.11M | $44.38M | $962.00K | (m) | 1.06% | 46.14× | Reported |
| 2014-06-30 | (m) | $282.40M | $2.97M | $43.01M | $858.00K | (m) | 1.05% | 50.13× | Reported |
| 2014-03-31 | (m) | $271.07M | $2.84M | $39.85M | $656.00K | (m) | 1.05% | 60.75× | Reported |
| 2013-12-31 | (m) | $264.06M | $2.74M | $38.77M | $538.00K | (m) | 1.04% | 72.06× | Reported |
| 2013-09-30 | (m) | $260.27M | $2.60M | $37.10M | $506.00K | (m) | 1.00% | 73.31× | Reported |
| 2013-06-30 | (m) | $255.87M | $2.43M | $36.17M | $515.00K | (m) | 0.95% | 70.23× | Reported |
| 2013-03-31 | (m) | $252.60M | $2.19M | $36.08M | $530.00K | (m) | 0.87% | 68.08× | Reported |
| 2012-12-31 | (m) | $252.09M | $2.10M | $37.80M | $557.00K | (m) | 0.83% | 67.87× | Reported |
| 2012-09-30 | (m) | $250.07M | $2.13M | $37.58M | $614.00K | (m) | 0.85% | 61.20× | Reported |
| 2012-06-30 | (m) | $246.89M | $2.11M | $36.84M | $621.00K | (m) | 0.86% | 59.32× | Reported |
| 2012-03-31 | (m) | $242.85M | $2.13M | $37.12M | $585.00K | (m) | 0.88% | 63.45× | Reported |
| 2011-12-31 | (m) | $237.01M | $2.03M | $35.93M | $496.00K | (m) | 0.86% | 72.44× | Reported |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $211.23M | $1.29M | $33.19M | $236.00K | (m) | 0.61% | 140.64× | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | $201.41M | $1.57M | $28.25M | $352.00K | (m) | 0.78% | 80.26× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Omada Health, Inc. (OMDA) | United States | $1.207B | 309.08 |
| InnovAge Holding Corp. (INNV) | United States | $1.206B | -635.60 |
| Pennant Group, Inc. (PNTG) | United States | $1.386B | 39.84 |
| Strata Critical Medical, Inc. (SRTA) | United States | $0.467B | 11.33 |
| DocGo Inc. (DCGO) | United States | $0.034B | -0.25 |
| Privia Health Group, Inc. (PRVA) | United States | $2.477B | 115.52 |
| VSEE HEALTH, INC. (VSEE) | United States | $0.003B | |
| Agape ATP Corp (ATPC) | $0.002B | ||
| GeneDx Holdings Corp. (WGS) | United States | $2.638B | -19.23 |
| LifeStance Health Group, Inc. (LFST) | United States | $4.510B | 80.86 |